Login
$INCY
$116.74 -$3.53 (2.93%) After hours

$INCY SEC Filings

Filed On Filing
16 Nov 2026 144
13 Nov 2026 144
13 Nov 2026 8-K: Other Events

Incyte Corporation (the “Company”) has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, the Company’s selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in pa...

12 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 Form 4: Stein Steven H, CMO & Head of Late-Stage Dev.

Received 240,193 shares by exercise or conversion ($19.5M) · Sold 240,193 shares ($28.4M)

06 Nov 2026 144
05 Nov 2026 Form 4: Tray Thomas, Principal Accounting Officer

Sold 610 shares ($72.6K)

03 Nov 2026 144
29 Oct 2026 10-Q
29 Oct 2026 8-K: Results of Operations and Financial Condition

Total revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to the third quarter of 2025

19 Oct 2026 Form 4: Cagnoni Pablo J, President, Global Head of R&D

Received 2,642 shares by exercise or conversion ($174K) · Sold 2,642 shares ($298K)

15 Oct 2026 144
05 Oct 2026 Form 4: Heeson Lee, EVP, Head of Incyte Intl

Gave up 463 shares to cover exercise price or tax ($54.2K)

02 Oct 2026 Form 4: Baker Bros. Advisors Lp, Director and 5 others

Received 644 shares as a grant or award

02 Oct 2026 Form 4: Clancy Paul J, Director

Received 203 shares as a grant or award ($24.6K)

02 Oct 2026 Form 4: Harrigan Edmund, Director

Received 206 shares as a grant or award ($25K)

24 Sep 2026 Form 4: Gardner David H, EVP, Chief Strategy Officer

Gave up 920 shares to cover exercise price or tax ($117K)

17 Sep 2026 Form 4: Cagnoni Pablo J, President, Global Head of R&D

Received 23,218 shares by exercise or conversion ($1.54M) · Sold 23,218 shares ($2.8M)

15 Sep 2026 144
31 Aug 2026 8-K: Other Events

Incyte Corporation (the “Company”) today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (“CMS”) intended to improve access to medicines for American patients while supporting contin...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support